EGFR degraders to treat cancer metastasis to the brain or CNS
MYPI2026003168A0Undetermined Publication Date: 2022-11-26C4 THERAPEUTICS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MYPI2026003168
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-21
- Filing Date
- 2022-05-26
- Publication Date
- 2022-11-26
Abstract
The invention provides for the treatment of mutant epidermal growth factor receptor (EGFR) mediated cancer that has metastasized to the brain or other area of the central nervous system with a compound that degrades a mutant form of EGFR via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The invention also provides advantageous drug combinations for the treatment of such cancer that include a compound herein that degrades a mutant form of EGFR in combination with a second anti-cancer agent. [Fig.2A]
Need to check novelty before this filing date? Find Prior Art
